Incredibly proud of our super ⭐️ Rutgers RWJ Urology research resident John Pfail - what a productive year - 🙏 representing us so well Saum Ghodoussipour Rutgers Cancer Institute #ASCO24 RWJBarnabas New York Section AUA #UroSoMe

Data for Gem/Doce for low volume (<30%, no LVI) micropapillary variant NMIBC. As per recently updated AUA guidelines, repeat TURBT (w/ blue light IMO) is particularly important for variant histologies Rutgers Cancer Institute Saum Ghodoussipour Ian McElree Bladder Cancer Advocacy Network pubmed.ncbi.nlm.nih.gov/38796357/

The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by Amanda Myers

Our latest paper on ctDNA detection using WGS is now published in European Urology. This WGS-based approach simplifies clinical workflows by eliminating the need for personalized assays. Read the paper here : doi.org/10.1016/j.euru…

A nice recent report on BCG strain differences and outcomes in patients with IR/HR NMIBC. pubmed.ncbi.nlm.nih.gov/37827948/ Remains to be resolved!!

Final results of #CORE001 trial out now Nature Medicine (1/14) 35 pts with BCG-UR CIS treated w/ Creto + pembro 👉12mo CR (per RBB) = 57.1% (ITT) 👉24mo CR = 54% *(Auth Corr) 👉No patient progressed to MIBC 👉No synergistic toxicity Gary Steinberg nature.com/articles/s4159…

Sent off our incredible chiefs Kevin Chua and Krishna at graduation yesterday. We can’t wait to see all that you achieve in the future! Saum Ghodoussipour Ji Hae Park, MD RoboUroMD Thomas Jang David Golombos Vignesh Packiam, MD Danielle Velez

Great study and interview on Gem/Doce for BCG-unresponsive NMIBC!! Inexpensive (~100x cheaper!) and highly effective (50% 2 year RFS) alternative to newer FDA approved agents Main limitation to Gem/Doce is retrospective - so its fantastic for our pts to have studies like these

Sequential gemcitabine and docetaxel show promise for intermediate-risk #NMIBC. Vignesh Packiam, MD Rutgers RWJ Urology joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss the emerging role of intravesical gem/doce for treating #NMIBC. #WatchNow > bit.ly/4aeVRiU

It's encouraging to see the lively discussion this has sparked. To clarify: we are not advocating for rescue BCG for all BCGU patients. What we are emphasizing is that if BCG were evaluated today in a single-arm registration study, it could likely be ‘approved’. While we must

Congrats Ben Lichtbroun, MD ! Looking forward to polishing you up for Fox Chase Cancer Center Department of Urology in your chief year Saum Ghodoussipour Thomas Jang David Golombos

Interesting paper! Another step closer to personalized treatment of NMIBC Cc Saum Ghodoussipour

Thrilled to share our latest publication on salvage HIFU for prostate cancer post-radiation failure! This review highlights patient selection criteria, promising disease control, and favorable outcomes compared to radical treatments tinyurl.com/2fpr3b2x Amir Lebastchi, MD

Watch Rutgers Cancer Institute's Dr. Vignesh Packiam Vignesh Packiam, MD weigh multiple recent studies that explore the efficacy of gemcitabine/docetaxel as a frontline therapy for upper tract urothelial #carcinoma. guoncologynow.com/post/sequentia… RWJBarnabas #UroOnc #Chemotherapy #KidneyCancer

Updated National Comprehensive Cancer Network (NCCN) guidelines (1.2025) are in, with some major changes for systemic therapies: 1) Ipi+Nivo is now a preferred regimen in fav-risk ccRCC 2) Len+Pem/Cabo+Nivo are now preferred regimens for non-clear cell RCC 3) Adjuvant Pembro is now Category 1 KidneyCAN

📺 #ICYMI: Vignesh Packiam, MD of Rutgers Cancer Institute, and KATIE MURRAY of NYU Langone Urology, weigh multiple recent studies that explore the efficacy of #gemcitabine/#docetaxel as a frontline therapy for #UTUC. 👉 Watch Now: buff.ly/4d25DH5

What an incredible team effort showcasing a daily reality: over 25% of #BladderCancer pts encounter mental health care barriers >urgent need for accessible programs. Despite progress in med coverage, mental health care remains out of reach for many #Oncology #MentalHealthMatters

Narrative review explores how to manage use of DOACs—apixaban, rivaroxaban, edoxaban, and dabigatran—in patients undergoing surgical and nonsurgical procedures to decrease risks of bleeding and thromboembolism. ja.ma/4fIm1hL

Sequential gemcitabine and docetaxel show promise for intermediate-risk #NMIBC. Vignesh Packiam, MD Rutgers RWJ Urology joins Sam S. Chang MD, MBA Vanderbilt Urology to discuss the emerging role of intravesical gem/doce for treating #NMIBC. #WatchNow > bit.ly/4aeVRiU

💯